<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02732418</url>
  </required_header>
  <id_info>
    <org_study_id>834119</org_study_id>
    <nct_id>NCT02732418</nct_id>
  </id_info>
  <brief_title>Lower Dose Depo Provera® Contraceptive Injection</brief_title>
  <official_title>A Study to Evaluate Suppression of Ovulation Following a Single Subcutaneous Administration of Various Doses of Depo-Provera CI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FHI 360</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FHI 360</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, partially-blinded, multi-center, parallel-group study to evaluate and&#xD;
      compare the PD and PK of MPA after a single SC injection of either 45 mg/0.3 mL, 75 mg/0.5 mL&#xD;
      or 105 mg/0.7 mL of Depo-Provera CI, and one cycle of Depo-subQ 104 use when injected in the&#xD;
      abdomen, in women of reproductive age with confirmed ovulatory baseline cycle&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, partially-blinded, multi-center, parallel-group study to evaluate and&#xD;
      compare the PD and PK of MPA after a single SC injection of either 45 mg/0.3 mL, 75 mg/0.5 mL&#xD;
      or 105 mg/0.7 mL of Depo-Provera CI, and one cycle of Depo-subQ 104 use when injected in the&#xD;
      abdomen, in women of reproductive age with confirmed ovulatory baseline cycle. Baseline&#xD;
      ovulation will be confirmed in all women by measuring serum progesterone (P) approximately&#xD;
      twice a week during the 2-3 weeks preceding expected menses. Between 48 and 60 participants&#xD;
      (12-15 per group) with confirmed ovulation who meet other eligibility criteria will be&#xD;
      enrolled and randomized to receive a single SC injection in the abdomen of 1 of 3 doses of&#xD;
      Depo-Provera CI: 45 mg/0.3 mL, 75 mg/0.5 mL or 105 mg/0.7 mL or a single dose of Depo-subQ&#xD;
      Provera (104 mg/0.65mL). Participants will be followed for 32 weeks (7.5 months) after the&#xD;
      injection During the study participants will provide blood samples for MPA, P and estradiol&#xD;
      (E2) prior to injection and then frequently at predefined time points through 7.5 months. In&#xD;
      addition, for more accurate ascertainment of the PD response we will perform transvaginal&#xD;
      ultrasound (TVS) and assess cervical mucus at predefined time points through 7.5 months.&#xD;
      Information on adverse events and concomitant medications will be collected throughout the&#xD;
      study. Information on acceptability will be collected at predefined time points through 7.5&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2, 2016</start_date>
  <completion_date type="Actual">May 15, 2018</completion_date>
  <primary_completion_date type="Actual">May 15, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to ovulation</measure>
    <time_frame>32 weeks after receiving drug</time_frame>
    <description>Time to ovulation indicated by time to reach rupture of the lead follicle based on transvaginal ultrasound (TVS) findings followed by serum progesterone level of &gt;=4.7 ng/mL. The primary objective will be assessed by estimating the cumulative probability of return to ovulation through Month 7.5 from start of therapy in each test group based on the Kaplan-Meier product-limit method, with 95% confidence intervals derived using the complementary log-log transformation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of serum MPA concentrations</measure>
    <time_frame>32 weeks after receiving drug</time_frame>
    <description>Measure of Peak Concentrations (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum serum concentration of MPA</measure>
    <time_frame>32 weeks after receiving drug</time_frame>
    <description>Time to reach peak concentration of MPA(Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse events</measure>
    <time_frame>32 weeks after receiving drug</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>Depo-Provera CI 45 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a single subcutaneous (SC) injection of 45 mg/0.3 mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Depo-Provera CI 75 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a single subcutaneous (SC) injection of 75 mg/0.5 mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Depo-Provera CI 105 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a single subcutaneous (SC) injection of 105 mg/0.7 mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Depo-subQ 104</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>a single subcutaneous (SC) injection of 104 mg/0.65 mL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Depo-Provera CI</intervention_name>
    <description>The active ingredient in Depo-Provera is Medroxyprogesterone acetate (MPA)</description>
    <arm_group_label>Depo-Provera CI 105 mg</arm_group_label>
    <arm_group_label>Depo-Provera CI 45 mg</arm_group_label>
    <arm_group_label>Depo-Provera CI 75 mg</arm_group_label>
    <other_name>Depo Provera® Contraceptive Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Depo-subQ 104</intervention_name>
    <description>The active ingredient in Depo-Provera is Medroxyprogesterone acetate (MPA). Depo-subQ provera 104® (medroxyprogesterone acetate injectable suspension, 104 mg/0.65mL) for subcutaneous injection</description>
    <arm_group_label>Depo-subQ 104</arm_group_label>
    <other_name>depo-subQ provera 104®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  has typical menstrual cycle of 24 to 35 days&#xD;
&#xD;
          -  has confirmed ovulatory cycle during the pretreatment phase (serum progesterone ≥ 4.7&#xD;
             ng/mL in 2 consecutive samples)&#xD;
&#xD;
          -  is sterilized or using non hormonal intrauterine device (IUD)&#xD;
&#xD;
          -  is in good general health as determined by a medical history and physical examination&#xD;
&#xD;
          -  18 to 40 years of age (inclusive)&#xD;
&#xD;
          -  willing to provide informed consent and follow all study requirements&#xD;
&#xD;
          -  has negative urine pregnancy test and has no desire to become pregnant in the&#xD;
             subsequent 12 months&#xD;
&#xD;
          -  has a body mass index (BMI) of 18.0 to 35.0 kg/m2, inclusive&#xD;
&#xD;
          -  has hemoglobin ≥10.5 g/dL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  has medical contraindications to depot medroxyprogesterone acetate (DMPA) [16]&#xD;
&#xD;
          -  has undiagnosed mass in breast&#xD;
&#xD;
          -  used DMPA in the past 12 months&#xD;
&#xD;
          -  used a combined injectable contraceptive in the past 6 months&#xD;
&#xD;
          -  used any of the following medications within 1 month prior to enrollment:&#xD;
&#xD;
               -  any investigational drug&#xD;
&#xD;
               -  prohibited drugs per protocol&#xD;
&#xD;
               -  oral contraceptives&#xD;
&#xD;
               -  Nuva-ring&#xD;
&#xD;
               -  contraceptive patch&#xD;
&#xD;
               -  levonorgestrel intrauterine system (LNG IUS) or contraceptive implant&#xD;
&#xD;
          -  has been pregnant within last 3 months&#xD;
&#xD;
          -  Is currently lactating&#xD;
&#xD;
          -  in the opinion of the investigator, is potentially at elevated risk of HIV infection&#xD;
             (HIV-positive partner, IV drug use by self or by partner)&#xD;
&#xD;
          -  has more than one male sexual partner&#xD;
&#xD;
          -  is using or plans to use prohibited drugs per protocol in the next 9 months&#xD;
&#xD;
          -  has known sensitivity to MPA&#xD;
&#xD;
          -  plans to move to another location in the next 9 months&#xD;
&#xD;
          -  has any condition (social or medical), which in the opinion of the investigator would&#xD;
             make study participation unsafe, would interfere with adherence to the clinical study&#xD;
             requirements or complicate data interpretation&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vera Halpern, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>FHI 360</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universidade Estadual de Campinas (UNICAMP)</name>
      <address>
        <city>CAmpinas</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Chileno De Medicina Reproductiva (ICMER)</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asociación Dominicana Pro Bienestar de la Familia, Inc. (PROFAMILIA)</name>
      <address>
        <city>Santo Domingo</city>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Chile</country>
    <country>Dominican Republic</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>March 30, 2016</study_first_submitted>
  <study_first_submitted_qc>April 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2016</study_first_posted>
  <last_update_submitted>June 12, 2018</last_update_submitted>
  <last_update_submitted_qc>June 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CI-contraceptive injection</keyword>
  <keyword>DMPA-Depot medroxyprogesterone acetate</keyword>
  <keyword>MPA-Medroxyprogesterone Acetate</keyword>
  <keyword>subQ-subcutaneous</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Medroxyprogesterone Acetate</mesh_term>
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Medroxyprogesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to share individual participant data</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

